Consensus Not Yet Reached on Key Drugs for Extensively Drug‐Resistant Tuberculosis Treatment | Zendy

Giovanni Battista Migliori | Zendy; Giovanni Sotgiu | Zendy; M. D’Arcy Richardson | Zendy; Rosella Centis | Zendy; Gunar Guenther | Zendy; Harald Hoffmann | Zendy; Daniela María Cirillo | Zendy; Olga Toungossova | Zendy; Kai Kliiman | Zendy; Saverio De Lorenzo | Zendy; Antonio Spanevello | Zendy; Christoph Lange | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Consensus Not Yet Reached on Key Drugs for Extensively Drug‐Resistant Tuberculosis Treatment

Author(s) -

Giovanni Battista Migliori,

Giovanni Sotgiu,

M. D’Arcy Richardson,

Rosella Centis,

Gunar Guenther,

Harald Hoffmann,

Daniela María Cirillo,

Olga Toungossova,

Kai Kliiman,

Saverio De Lorenzo,

Antonio Spanevello,

Christoph Lange

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/600060

Subject(s) - medicine , tuberculosis , drug , intensive care medicine , drug resistance , extensively drug resistant tuberculosis , medline , pharmacology , mycobacterium tuberculosis , microbiology and biotechnology , pathology , biology , political science , law

Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) are increasing in frequency globally and are difficult to treat. Although treatment successes have been reported, there are no definitive clinical studies available that show which classes or combinations of available drugs are most effective in yielding\udpositive treatment outcomes

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research